Latest Content

10 of 3481 Shown
  • Immune Checkpoint Blockade in Advanced Lung Cancer Patients: Optimizing Treatment Duration

    H. Jack West MD - 9/30/2016
    How long should we continue patients with NSCLC on immune checkpoint inhibitors? H. Jack West, MD, shares his thoughts on this clinically important issue.
  • How I Treat Young, Fit Patients With Newly Diagnosed Non-del(17p) CLL

    Farrukh Awan MD, MS - 9/29/2016
    How do the latest data affect treatment selection for individual patients with newly diagnosed CLL who do not have specific genetic abnormalities?
  • Designing a New Approach to Clinical Trials in AML

    Harry P. Erba MD - 9/28/2016
    Harry P. Erba, MD, discusses the challenge of, and possible solution for, developing an effective trial for elderly patients with AML who are unfit for chemotherapy.
  • Best Practices and Promising Agents in Pancreatic Cancer

    In this archived webcast from the CCO Pancreatic Local Live meeting series, Andrew H. Ko, MD, provides expert perspective on optimizing treatment choices for patients with advanced or metastatic pancreatic cancer.
    Date Posted: 9/28/2016
  • Learning Module cme-icon

    Acute Leukemias: A Collection of Expert Commentaries

    This activity includes a collection of commentaries focused on acute leukemias. Various experts provide practical perspectives on recent treatment advances and everyday clinical challenges.
    Faculty: Dan Douer MD, Farhad Ravandi MD, B. Douglas Smith MD, Jonathan Webster MD
    Released: 9/27/2016
  • At a Glance: Caring for Patients With Advanced Pancreatic Cancer

    A nursing resource with information on staging, diagnosis, and treatment of advanced pancreatic cancer, including adverse event management, with helpful guide for using shared decision making to improve patient outcomes and satisfaction with care.
    Date Posted: 9/27/2016
  • My Experiences Managing Pneumonitis and Hypophysitis in Patients Receiving Checkpoint Inhibitor Therapy

    Jeffrey S. Weber MD, PhD - 9/26/2016 2 comments / Last Comment: 9/30/2016
    Using 2 real-world clinical scenarios, this commentary focuses on practical strategies to manage pulmonary and endocrine adverse events associated with checkpoint inhibition in melanoma.
  • Learning Module cme-icon

    Immunotherapy: A Review of Key Clinical Studies

    David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, each provide an analysis of key presentations on cancer immunotherapy from the 2016 clinical oncology meeting in Chicago.
    Faculty: David R. Gandara MD, Daniel M. Geynisman MD, Sara Hurvitz MD, FACP, Elias Jabbour MD, Shaji Kumar MD, Brian Rini MD, FACP, Tiffany A. Traina MD, Heather Wakelee MD
    Released: 9/23/2016
  • How I Am Using CDK4/6 Inhibitors for My Patients With Hormone Receptor–Positive MBC

    Mohammad  Jahanzeb MD, FACP - 9/21/2016 2 comments / Last Comment: 9/29/2016
    Are you considering CDK4/6 inhibitors as part of your treatment armamentarium for patients with hormone receptor–positive metastatic breast cancer? Dr. Jahanzeb provides insights from his experience.
  • Clinical Focus cme-icon

    How Newly Approved Agents Can Improve the Management of Relapsed/Refractory Multiple Myeloma

    In this interactive, CME-certified module, Sagar Lonial, MD, provides expert perspective on advances in the treatment of patients with relapsed/refractory multiple myeloma.
    Faculty: Sagar Lonial MD
    Released: 9/20/2016
10 of 3481 Shown
Show 10 More
Decision Support
Immediate answers to treatment questions
More than just up to date